Molina Healthcare will pull its Medicare Advantage prescription drug plans from the market for the 2027 plan year, retreating to the dual-eligible business that has become its core. Members enrolled in those plans will see coverage end on December 31 and must select something new during Medicare’s fall Open Enrollment. The move is one company’s response to losses in a single product line, but for the households holding those plans it means a forced switch on a fixed calendar, not an optional one.
Why Molina is walking away from its drug plans
The decision is financial. Molina disclosed the exit alongside its 2025 earnings early this year, telling investors that its Medicare Advantage prescription drug product — worth roughly a billion dollars in annual premiums — was losing money and weighing on earnings. Rather than reprice the plans and try to make them work, the insurer chose to leave the product line entirely for 2027.
The retreat fits a deliberate strategy. Molina has said it wants to concentrate on its dual-eligible business, the far larger operation serving people who qualify for both Medicare and Medicaid, and that its general Medicare Advantage drug plans did not fit that focus. The standalone drug plan sold to ordinary enrollees is the piece being cut; the dual-eligible plans remain in place.
For members, the corporate rationale matters less than the timing. A plan that is being discontinued does not simply continue at a higher premium the following year — it disappears, and the coverage has to be actively replaced before the new year begins or it lapses.
Free retirement updates: Miss an enrollment or claim deadline and it may be gone. Our free Retirement Shield newsletter keeps readers ahead of the ones that matter. Get the free newsletter.
What affected members must do this fall
Molina will send non-renewal notices to affected enrollees, and the main window to act is Medicare’s Open Enrollment, which runs October 15 through December 7. A member who chooses a new Medicare Advantage plan, or a combination of Original Medicare and a standalone Part D plan, during that period begins fresh coverage on January 1 with no gap.
There is a backstop for anyone who misses the deadline. When a plan leaves the market, its members generally qualify for a special enrollment period that extends past December 7, giving them additional time in early 2027 to pick replacement coverage. Leaning on it is riskier than acting during Open Enrollment, because a gap in drug coverage can trigger a late-enrollment penalty and leave prescriptions unpaid in the meantime.
That backstop has a defined shape. Because the plan is leaving Medicare, affected members qualify for a special enrollment period running from December 8 through the last day of February, which lets them select a replacement in the opening weeks of 2027 if the Open Enrollment deadline passes. It removes the risk of being locked out entirely, but it does not remove the risk of a gap, and a gap in drug coverage is where the real cost hides.
That cost is the Part D late-enrollment penalty. A beneficiary who goes 63 days or more without creditable drug coverage is charged a permanent surcharge equal to one percent of the national base beneficiary premium — $38.99 for 2026 — for each uncovered month, folded into every future premium. A member who drifts past Open Enrollment and leaves a stretch of early 2027 uncovered can convert a temporary lapse into a charge that follows them for as long as they carry Part D.
The switch also warrants a close look at the details, not just the premium. A replacement plan carries its own network of pharmacies and doctors and its own drug formulary, so a member should confirm that current medications are still covered and at what tier before enrolling, rather than assuming the new plan will behave like the old one.
The dual-eligible plans Molina is keeping
The exit is selective, and the distinction matters for who has to act. Molina is dropping the general-market Medicare Advantage drug plan sold to ordinary enrollees, but it is keeping the dual-eligible special-needs plans that serve people qualified for both Medicare and Medicaid — the roughly five-billion-dollar business it is consolidating around. A member needs to know which product they hold, because a dual-eligible enrollee in a retained plan is not necessarily among those being forced to switch this fall.
That makes identifying the exact plan the first task, ahead of any shopping. A notice about the general-market drug plan does not touch a Molina dual-eligible enrollee, and a household that assumes the two are the same could scramble to replace coverage that was never at risk — or, worse, overlook a notice that genuinely applies. The single question that resolves it is which Molina product the member is actually enrolled in for 2026.
A single exit inside a broader contraction
Molina’s departure is not isolated. The largest Medicare Advantage insurers, including UnitedHealth and Humana, are shedding plans covering hundreds of thousands of members apiece for 2027 as rising medical costs make the business harder to run at a profit. Molina’s exit from its drug plans is a smaller version of the same retreat, driven by the same math.
For enrollees, the pattern is the real lesson. A Medicare Advantage plan is renewed year to year at the insurer’s discretion, and a plan that looks stable can vanish when the economics turn against it. The members Molina is dropping have a defined task this fall — replace the coverage before the deadline — but the wider signal is to read every annual notice carefully, because the plan that covers a household today is not guaranteed to exist next year.
This article was produced with AI assistance and reviewed against primary sources by The Money Overview editorial team.
More Financial Reading
